Literature DB >> 28160067

Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

Keith A Josephs1,2, Melissa E Murray3, Nirubol Tosakulwong4, Jennifer L Whitwell5, David S Knopman6, Mary M Machulda7, Stephen D Weigand4, Bradley F Boeve6, Kejal Kantarci5, Leonard Petrucelli3, Val J Lowe5, Clifford R Jack5, Ronald C Petersen6, Joseph E Parisi8, Dennis W Dickson3.   

Abstract

We investigate whether there is any association between the Braak neurofibrillary tangle (NFT) stage and clinical and MRI features in definite primary age-related tauopathy (PART). We analysed 52 cases with a Braak NFT tangle stage >0 and ≤IV, and a Thal phase of 0 (no beta-amyloid present). Twenty-nine (56%) were female. Median age at death was 88 years (IQR 82-92 years). Fifteen (29%) were TDP-positive (75% TDP stage I), 16 (31%) had argyrophilic grain disease and three (6%) had alpha-synuclein-positive Lewy bodies. TDP-43 inclusion when present were rare and predominantly perivascular. Of the 15 with TDP-43, three showed a moderate number of inclusions and also had hippocampal sclerosis, neuronal intranuclear inclusions and fine neurites of the CA1 region of the hippocampus. Four cases (8%) had an apolipoprotein epsilon 4 (APOE4) allele. There was a significant correlation between age at death and Braak NFT stage (r = 0.32, p = 0.02). After accounting for age at clinical examination, there were significant associations between Braak NFT stage, and WAIS-R Block Design and Trail Making Tests A and B, with higher Braak stage associated with poorer performances. Thirty of the 52 cases had completed an antemortem volumetric head MRI. Two separate MRI analyses revealed an association between higher Braak NFT stage and grey matter atrophy in the head of the left hippocampus. There were no significant clinical or radiologic associations with TDP-43. Findings from this study demonstrate that aggregated tau distribution is associated with poorer cognitive performance, as well as atrophy, in the absence of beta-amyloid. These findings support the parcellation of definite PART as a useful construct. The relatively low frequencies of APOE4, TDP-43, Lewy bodies, and hippocampal sclerosis, and the rarity and morphology of TDP-43 lesions are noted contrasts to what is typically observed in Alzheimer's disease of the old.

Entities:  

Keywords:  Alzheimer’s disease; Beta-amyloid; Cognition; Hippocampus; MRI; Neurofibrillary tangles; PART; TDP-43; Tauopathy

Mesh:

Substances:

Year:  2017        PMID: 28160067      PMCID: PMC6091858          DOI: 10.1007/s00401-017-1681-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  59 in total

1.  The Mini-Mental State Examination.

Authors:  M F Folstein; L N Robins; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1983-07

Review 2.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

3.  Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.

Authors:  K A Jellinger; J Attems
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

4.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

5.  TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Authors:  Keith A Josephs; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; Robert J Ivnik; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Ann Neurol       Date:  2015-09-16       Impact factor: 10.422

6.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

7.  Processing speed in normal aging: effects of white matter hyperintensities and hippocampal volume loss.

Authors:  Kathryn V Papp; Richard F Kaplan; Beth Springate; Nicola Moscufo; Dorothy B Wakefield; Charles R G Guttmann; Leslie Wolfson
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2013-07-29

Review 8.  Semantic dementia: a unique clinicopathological syndrome.

Authors:  John R Hodges; Karalyn Patterson
Journal:  Lancet Neurol       Date:  2007-11       Impact factor: 44.182

9.  Updated TDP-43 in Alzheimer's disease staging scheme.

Authors:  Keith A Josephs; Melissa E Murray; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Leonard Petrucelli; Amanda M Liesinger; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2016-01-25       Impact factor: 17.088

10.  Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?

Authors:  John F Crary
Journal:  J Neurol Neuromedicine       Date:  2016
View more
  64 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

Review 2.  Biomarkers for neurodegenerative diseases.

Authors:  Oskar Hansson
Journal:  Nat Med       Date:  2021-06-03       Impact factor: 53.440

3.  Differences in Cognitive Impairment in Primary Age-Related Tauopathy Versus Alzheimer Disease.

Authors:  Lilah M Besser; Charles Mock; Merilee A Teylan; Jason Hassenstab; Walter A Kukull; John F Crary
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

Review 4.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

5.  Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease.

Authors:  W Robert Bell; Yang An; Yusuke Kageyama; Collin English; Gay L Rudow; Olga Pletnikova; Madhav Thambisetty; Richard O'Brien; Abhay R Moghekar; Marilyn S Albert; Peter V Rabins; Susan M Resnick; Juan C Troncoso
Journal:  Alzheimers Dement       Date:  2018-12-11       Impact factor: 21.566

6.  Fitting TDP-43 into the APOE ε4 and neurodegeneration story.

Authors:  Keith A Josephs
Journal:  Lancet Neurol       Date:  2018-08-06       Impact factor: 44.182

7.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

Review 8.  Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related Tauopathy.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Continuum (Minneap Minn)       Date:  2019-02

9.  Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.

Authors:  Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.